QLT PhotoTherapeutic/Sanofi Photofrin
Oncologic advisory committee will discuss application supplement (sNDA 20-451/03) for Photofrin (porfimer sodium) on the afternoon of Sept. 3 for reduction of obstruction and palliation of symptoms in patients with completely or partially obstructing endobronchial non-small-cell lung cancer. The company submitted a reanalysis of data for the indication after the committee voted against approval in September and a narrower NSCLC indication was granted ("The Pink Sheet" Jan. 12, T&G-15)
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth